)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Crescita Therapeutics
Crescita Therapeutics (CTX) investor relations material
Crescita Therapeutics has been acquired
Crescita Therapeutics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary11 May, 2026
Executive summary
Q1 2026 revenue was $5.64M, up $2.1M year-over-year, driven by growth in Commercial Skincare and Manufacturing segments, including new skincare assets and higher manufacturing volumes.
Gross profit increased to $2.64M, with a gross margin of 46.9%, up 2.5 percentage points year-over-year.
Net loss widened to $1.16M from $0.93M, mainly due to higher SG&A and operating expenses, including $825K in transaction costs related to a pending acquisition.
Adjusted EBITDA turned positive at $238K, a $917K improvement year-over-year, reflecting operational improvements and exclusion of non-recurring costs.
Cash and cash equivalents at quarter-end were $8.71M, up $133K from the previous quarter.
Financial highlights
Operating expenses rose to $3.85M, up $1.22M year-over-year, primarily due to transaction and share-based compensation costs.
SG&A expenses increased by $1.19M, mainly from acquisition-related legal and advisory fees and higher share-based compensation.
Cash provided by operating activities was $142K, compared to cash used of $513K in Q1 2025.
No amounts drawn on the $3.5M revolving credit facility; working capital stood at $10.17M.
Revenue: $5.64M (Q1 2026) vs. $3.54M (Q1 2025), up $2.1M.
Outlook and guidance
Management expects sufficient liquidity to fund operations and execute its Four-Pillar Growth Strategy, focusing on operational priorities and a smooth transition pending the ClinActiv Holdings acquisition.
The pending acquisition by ClinActiv Holdings is expected to close in Q2 2026, subject to shareholder and court approval.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Crescita Therapeutics
- Q2 revenue fell 21% with a net loss of $0.9M, but new contracts and acquisitions target future growth.CTX
Q2 2024 - Revenue grew, losses narrowed, and a premium acquisition by ClinActiv is pending.CTXQ4 2025
- Q3-25 revenue rose 50% to $5.39M, net income hit $753K, and cash reserves reached $8.3M.CTXQ3 2025
- Q1-25 revenue fell 29% to $3.54M, net loss widened, but outlook anticipates recovery.CTXQ1 2025
- Revenue up 52% to $6.2M, net income $0.8M, driven by new contracts and a $902K payment.CTXQ2 2025
- Growth driven by new contracts, acquisition, and a focus on recurring revenue and U.S. expansion.CTXPlanet MicroCap Showcase: VANCOUVER 2024
- Revenue up 18.5% to $3,594,000, net loss narrowed, and new deals support future growth.CTXQ3 2024
- Revenue up, gross margin down; strategic deals and acquisitions support future growth.CTXQ4 2024
Crescita Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Crescita Therapeutics Inc. is a Canadian company engaged in the commercial dermatology sector. It specializes in both prescription and non-prescription skincare products aimed at treating various skin conditions and diseases. Crescita's product portfolio includes a notable prescription product, Pliaglis, which utilizes a proprietary phase-changing cream technology and is available in over 40 countries. The company is headquartered in Laval, Quebec, and its shares are listed on the Toronto Stock Exchange.